Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $10.00 price target on AbCellera Biologics (NASDAQ: ABCL).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE